Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Leonard S. Marks

University of California at Los Angeles and Urological Sciences Research Foundation

Los Angeles

USA

[email]@ucla.edu

Name/email consistency: high

[Claim this account]

Affiliations

University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, USA. 2009 - 2013
Department of Urology, University of California, Los Angeles, Geffen School of Medicine, USA. 2006 - 2009
Urological Sciences Research Foundation, Culver City, California 90232, USA. 2003 - 2007
Department of Urology, Geffen School of Medicine at UCLA, Urological Sciences Research Foundation, 3831 Hughes Avenue, USA. 2006 - 2007
Urological Sciences Research Foundation and Department of Urology, UCLA School of Medicine, Los Angeles, California, USA. 2001 - 2006

References

Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. Marks, L.S., Gittelman, M.C., Hill, L.A., Volinn, W., Hoel, G. J. Urol. (2013) [Pubmed]
Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. Marks, L.S., Gittelman, M.C., Hill, L.A., Volinn, W., Hoel, G. J. Urol. (2009) [Pubmed]
Words of wisdom. Re: Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Marks, L.S. Eur. Urol. (2009) [Pubmed]
Prostate tissue androgens: history and current clinical relevance. Marks, L.S., Mostaghel, E.A., Nelson, P.S. Urology (2008) [Pubmed]
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Marks, L.S., Fradet, Y., Deras, I.L., Blase, A., Mathis, J., Aubin, S.M., Cancio, A.T., Desaulniers, M., Ellis, W.J., Rittenhouse, H., Groskopf, J. Urology (2007) [Pubmed]
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. Marks, L.S., Roehrborn, C.G., Wolford, E., Wilson, T.H. J. Urol. (2007) [Pubmed]
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. Marks, L.S., Andriole, G.L., Fitzpatrick, J.M., Schulman, C.C., Roehrborn, C.G. J. Urol. (2006) [Pubmed]
Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. Marks, L.S., Hess, D.L., Dorey, F.J., Macairan, M.L. Urology (2006) [Pubmed]
Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease. Marks, L.S. Curr. Urol. Rep (2006) [Pubmed]
Prevention of benign prostatic hyperplasia disease. Marks, L.S., Roehrborn, C.G., Andriole, G.L. J. Urol. (2006) [Pubmed]
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Marks, L.S., Mazer, N.A., Mostaghel, E., Hess, D.L., Dorey, F.J., Epstein, J.I., Veltri, R.W., Makarov, D.V., Partin, A.W., Bostwick, D.G., Macairan, M.L., Nelson, P.S. JAMA (2006) [Pubmed]
Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Marks, L.S. Urology (2003) [Pubmed]
The role of prostate needle biopsy in evaluation of chemopreventive agents. Marks, L.S., Epstein, J.I., Partin, A.W. Urology (2001) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.